CBRS21001 / A011801 / Dhakal
Basic Study Information
Purpose:
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib
work in preventing breast cancer from coming back (relapsing) in patients with high
risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab,
linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy
because it attaches to specific molecules (receptors) on the surface of cancer cells,
known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1
and tucatinib may work better in preventing breast cancer from relapsing in patients
with HER2 positive breast cancer compared to T-DM1 alone.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Ajay Dhakal
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search